Bayer Sues Lupin Over Generic Cipro

Law360, New York (February 19, 2010, 1:23 PM EST) -- Bayer Schering Pharma AG has hit Indian drugmaker Lupin Ltd. with a patent infringement suit over plans to introduce generic versions of Cipro, the branded form of anti-microbial drug ciprofloxacin.

Bayer filed suit against Lupin and its U.S. subsidiary on Thursday in the U.S. District Court for the District of Maryland, in response to several abbreviated new drug applications Lupin has filed with the U.S. Food and Drug Administration.

Lupin's planned drugs — 250mg/5mL and 500mg/5mL versions of Cipro oral suspension — infringe Bayer-held U.S. Patent...
To view the full article, register now.